Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $55
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. EWTX | 0.00 |
Evercore ISI Group analyst Cory Kasimov maintains Edgewise Therapeutics (NASDAQ:
EWTX) with a Outperform and raises the price target from $45 to $55.
